@entity15451 is effective in XXXX complicating chronic hemodialysis.

@entity1 @entity390 @entity39 @entity2316 @entity391 @entity740 @entity730 @entity15451 @entity74 @entity158 @entity13375
BACKGROUND: @entity730 ( @entity730 ) or @entity13375 is a severe complication of advanced @entity740 ( @entity740 ) and dialysis. Few effective treatments are available and the mortality rate is high. We report 4 cases in which @entity15451 therapy was rapidly effective. CASES: @entity15451 therapy was given to 4 Caucasian @entity1 (3 females and 1 male aged 49 to 91 years) with @entity730 . The causes of end-stage @entity740 were nephroangiosclerosis (n=2) and @entity2316 (n=2). The lesions developed 1 to 6.5 years after the initiation of hemodialysis and involved the lower limbs in 2 @entity1 , the fingers in 1 @entity1 , and a breast in the remaining @entity1 . They were responsible for @entity158 and @entity39 in all 4 @entity1 . Local superinfection occurred in 3 @entity1 . Intravenous @entity15451 was given in a dosage of 12.5 to 25g after each hemodialysis session, for 12 to 24 weeks. The @entity158 and @entity74 resolved fully in all 4 @entity1 . The side effects consisted of @entity390 and @entity391 (n=2) and a moderate blood pressure decrease (n=1). No recurrences were noted during the follow-up of 5 to 17 months after treatment discontinuation. CONCLUSION: The findings from this small case-series suggest that @entity15451 may hold promise for the treatment of @entity730 .
